H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...

Axsome's stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth. See why I maintain ...

Axsome Therapeutics Inc. shares dipped over 2% on Tuesday — their worst session in nearly two weeks — after the company ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective lifted by equities research analysts at Needham & Company LLC from $133.00 to $153.00 in a report released on ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Needham raised the firm’s price target on Axsome Therapeutics (AXSM) to $153 from $133 and keeps a Buy rating on the shares. The company’s Q4 ...

Cantor Fitzgerald reaffirmed their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. They ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Axsome Therapeutics gained more than $1 billion in market value Monday, after the brain drug developer disclosed a patent ...

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% ...